Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cross-tumoral Phase 2 Clinical Trial Exploring Crizotinib (PF-02341066) in Patients With Advanced Tumors Induced by Causal Alterations of ALK and/or MET ("CREATE")

NCT01524926 is registered in ClinicalTrials.gov with European Organisation for Research and Treatment of Cancer - EORTC as lead sponsor.

NCT NCT01524926
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01524926 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cross-tumoral Phase 2 Clinical Trial Exploring Crizotinib (PF-02341066) in Patients With Advanced Tumors Induced by Causal Alterations of ALK and/or MET ("CREATE")
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2012
Completion date
October 30, 2022
Enrollment
582 (estimated)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced and/or metastatic alveolar rhabdomyosarcoma, locally advanced and/or metastatic alveolar soft part sarcoma, locally advanced and/or metastatic anaplastic large cell lymphoma, locally advanced and/or metastatic clear cell sarcoma, locally advanced and/or metastatic inflammatory myofibroblastic tumor, locally advanced and/or metastatic papillary renal cell carcinoma type 1